A major clinical trial on puberty blockers for gender-questioning youth is moving forward after a High Court ruling clears the way. The Pathways trial, launching August 1st with over 220 kids aged 11–16, will rigorously assess impacts on bone density, brain development, fertility, and mental health—especially as existing evidence remains sparse. Though campaigners challenged the ethics and consent process, the court dismissed their claims, citing thorough medical evaluations for each participant. Researchers at King’s College London praise the safeguards, while parents and advocates express disappointment, seeing this as a pivotal global moment. The trial’s age limits were adjusted following regulatory review, allowing girls from 11 and boys from 12. It now proceeds under new government guidelines restricting blockers to controlled research settings, with existing users unaffected.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
